Best Ideas Portfolio

Official PayPal Seal

Pfizer, Eli Lilly Post Fourth-Quarter Results; Both Score High on Our Valuentum Dividend Cushion

publication date: Jan 31, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer and Eli Lilly posted fourth-quarter results with each showing the impact of the industry's "patent cliff." Pfizer has lost exclusivity of Lipitor, while Eli Lilly is now facing competition for its blockbuster drug Zyprexa. Though their respective outlooks remain challenged, the safety of their current dividends remains excellent based on their respective Valuentum Dividend Cushion scores.

Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.